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The 100 000 Genomes Project described by Clare Turnbull and
colleagues1 is a world leading initiative offering welcome
opportunities for patients with rare and undiagnosed conditions.
But the challenges of delivering results cannot be minimised.
Recruitment is behind schedule and only reached halfway in
February, three years into the project, which is due to end this
October. Reporting times remain longer than planned: we have
received results for only a fraction of the 80 plus families
recruited in our paediatric dermatology department. The use of
targeted gene panels is speeding up turnaround and (helpfully)
reducing the number of variants of unknown significance, but
this generates many negative reports—patients will not be
satisfied with “no mutation found,” and those cases require a
robust system of further interrogation.
Systems for multidisciplinary discussion and feedback to
patients, particularly those recruited outside clinical genetics
departments, are not yet established. With colleagues at the
West Midlands Genomic Medicine Centre we are building a
specialty network to support interpretation of results and
incorporation of genomic testing into routine clinical practice
after the 100 000 Genomes Project. Our recent regional survey
confirmed that only a handful of dermatologists are actively
recruiting, but most want to be involved in discussion of their
patients’ results. Time pressures preclude regular face-to-face
multidisciplinary team meetings, but colleagues would access
an online conferencing solution.
We strongly support the 100 000 Genomes Project. At our first
“dermatogenetic” multidisciplinary team meeting we discussed
an undiagnosed disorder with an unexpected mutation, raising
the important possibility of a novel disease with an unsuspected
susceptibility to cancer. We look forward to seeing the ideals
of the 100 000 Genomes Project effectively realised and
translated into future NHS genomic testing, but pragmatic
solutions must quickly be found to ensure that patients receive
validated and useful results in a timely manner.
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